RT Journal Article
SR Electronic
T1 Outcome reporting from protocols of clinical trials of Coronavirus Disease 2019 (COVID-19): a review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.04.20031401
DO 10.1101/2020.03.04.20031401
A1 Qiu, Ruijin
A1 Wei, Xuxu
A1 Zhao, Mengzhu
A1 Zhong, Changming
A1 Zhao, Chen
A1 Hu, Jiayuan
A1 Li, Min
A1 Huang, Ya
A1 Han, Songjie
A1 He, Tianmai
A1 Chen, Jing
A1 Shang, Hongcai
YR 2020
UL http://medrxiv.org/content/early/2020/03/08/2020.03.04.20031401.abstract
AB Objectives To examine heterogeneity of outcomes in protocols of clinical trials of Coronavirus Disease 2019 (COVID-19) and to identify outcomes for prioritization in developing a core outcome set (COS) in this field.Design This study is a review.Data sources Databases of ICMJE-accepted clinical trial registry platform were searched on February 14, 2020.Eligibility Criteria Randomized controlled trials (RCTs) and non-RCTs of COVID-19 were considered. Conditions of patients include common type, severe type or critical type. Interventions include traditional Chinese medicine (TCM) and Western medicine. We excluded trials that for discharged patients, psychological intervention and complications of COVID-19.Data extraction and synthesis The general information and outcomes, outcome measurement instruments and measurement times were extracted. The results were analysed by descriptive analysis.Results 19 registry platforms were searched. A total of 97 protocols were included from 160 protocols. For protocols of TCM clinical trials, 76 outcomes from 16 outcome domains were reported, and almost half (34/76, 44.74%) of outcomes were reported only once; the most frequently reported outcome was time of SARS-CoV-2 RNA turns to negative. 27 (27/76, 35.53%) outcomes were provided one or more outcome measurement instruments. 10 outcomes were provided one or more measurement time frame. For protocols of western medicine clinical trials, 126 outcomes from 17 outcome domains were reported; almost half (62/126, 49.21%) of outcomes were reported only once; the most frequently reported outcome was proportion of patients with negative SARS-CoV-2. 27 outcomes were provided one or more outcome measurement instruments. 40 (40/126, 31.75%) outcomes were provided one or more measurement time frame.Conclusion Outcome reporting in protocols of clinical trials of COVID-19 is inconsistent. Thus, developing a core outcome set is necessary.Strengths and limitations of this study1. This review is the first to describe variation in outcomes, outcome measurement instruments and outcome measurement time reporting in clinical trials for Coronavirus Disease 2019 (COVID-19).2. All the database of ICMJE-accepted clinical trial registry platform were searched, and randomized controlled trials and observational studies were considered.4. The aim of this review was to provide a list of outcomes for clinical trials of COVID-19, both interventions of Traditional Chinese Medicine and western medicine were considered.5. When the searching was conducted, no clinical trials were registered by countries out of China, so all of included protocols were from China.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols http://www.comet-initiative.org/Studies/Details/1507 Funding StatementThis work was supported by the National High-level Personnel of Special Support Program [W02020052].Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is from public database and does not include identifiable patient data.